DISOPYRAMIDE

/static/temp/default.svg

Search structure


Synonyms	(rs)-disopyramide Dicorantil Disopyramide Dl-disopyramide H-3292 Isorythm Lispine Norpace Ritmilen Rythmodan p SC-7031 Searle-703
Status
Molecule Category	Free-form
ATC	C01BA03
UNII	GFO928U8MQ
EPA CompTox	DTXSID1045536


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UVTNFZQICZKOEM-UHFFFAOYSA-N
Smiles	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
InChI	InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H29N3O
Molecular Weight	339.48
AlogP	3.36
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	8.0
Polar Surface Area	59.22
Molecular species	BASE
Aromatic Rings	2.0
Heavy Atoms	25.0

Assay Description	Organism	Bioactivity	Reference
Parasympatholytic activity and the % inhibition of guinea pig ileum contractile force at 4 mg/L of base was reported.	Cavia porcellus	81.0 %
Parasympatholytic activity was assessed from the ability to inhibit electrically stimulated contraction of isolated guinea pig ileum at 4 mg/L of base	Cavia porcellus	81.0 %
Anticholinergic activity is assessed in guinea pig ileum at 3 uM	Cavia porcellus	363.08 nM
Antimuscarinic activity in guinea pig ileum	Cavia porcellus	891.25 nM
Inhibitory effect on muscarinic acetylcholine receptor binding affinity at a concentration of (10e -5)M	None	7.0 %
Inhibitory effect on muscarinic acetylcholine receptor binding affinity at a concentration of (10e -6)M	None	-1.0 %
Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel	Cavia porcellus	14.0 %
Percentage inhibition of specific binding of [3H]batrachotoxin [3H]BTX) in sodium channel from cardiac myocytes at 10 uM	Rattus norvegicus	17.0 %
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	Homo sapiens	68.8 %
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	Homo sapiens	47.5 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	Homo sapiens	8.6 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	Homo sapiens	18.5 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	26.69 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.19 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.19 %

Cross References

Resources	Reference
ChEBI	4657
ChEMBL	CHEMBL517
DrugBank	DB00280
DrugCentral	926
FDA SRS	GFO928U8MQ
Human Metabolome Database	HMDB0014425
Guide to Pharmacology	7167
KEGG	C06965
PharmGKB	PA449373
PubChem	3114
SureChEMBL	SCHEMBL16153

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).